Literature DB >> 22083365

Molecular Adsorbents Recirculating System dialysis in children with cholestatic pruritus.

Betti Schaefer1, Franz Schaefer, Dieter Wittmer, Guido Engelmann, Daniel Wenning, Claus Peter Schmitt.   

Abstract

BACKGROUND: Cholestatic pruritus may severely compromise quality of life. The Molecular Adsorbents Recirculating System (MARS) allows removal of pruritogenic substances without exposure to foreign proteins. Pediatric data, however, are scant.
METHODS: We retrospectively analyzed the efficacy of MARS in three boys with severe cholestatic pruritus. They received a total of 135 MARS sessions during 8, 4, and 13 months prior to liver transplantation. Total serum bilirubin and bile acids were monitored, and pruritus was assessed by a numerical rating scale (NRS 0 = no pruritus, 10 = maximal pruritus).
RESULTS: MARS sessions were initially performed three times weekly at a mean duration of 6.3 ± 1.4 h. Sessions could be reduced to once weekly and once every other week in two patients. Pre-MARS plasma bile acid concentrations averaged 207 ± 67 μmol/l. They declined to 67 ± 9%, 48 ± 3%, 38 ± 14%, and 37 ± 5% of baseline within 2, 4, 6 and 8 h of therapy, respectively (all p < 0.05). The average interdialytic increase of plasma bile acids was 34 ± 33 μmol/l per day. Mean NRS score decreased from 6.5 ± 2.3 to 3.3 ± 2.9 (p < 0.01). Skin lesions from itching disappeared. All MARS treatments were well tolerated.
CONCLUSION: MARS dialysis substantially reduces cholestatic pruritus in children refractory to pharmacological treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083365     DOI: 10.1007/s00467-011-2058-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  40 in total

1.  Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure.

Authors:  P Sorkine; R Ben Abraham; O Szold; P Biderman; A Kidron; H Merchav; S Brill; R Oren
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 2.  The pruritus of cholestasis.

Authors:  Nora V Bergasa
Journal:  J Hepatol       Date:  2005-10-06       Impact factor: 25.083

3.  Treatment of intractable pruritus in patients with cholestatic jaundice by plasma exchange and plasma perfusion.

Authors:  P Geerdink; P Snel; G P van Berge Henegouwen; A Huybregts; A Tangerman; V A Kunst; J H van Tongeren
Journal:  Neth J Med       Date:  1978       Impact factor: 1.422

4.  Uptake and efflux of the peptidic delta-opioid receptor agonist.

Authors:  C Dagenais; J Ducharme; G M Pollack
Journal:  Neurosci Lett       Date:  2001-04-06       Impact factor: 3.046

Review 5.  Multidrug resistance in brain tumors: roles of the blood-brain barrier.

Authors:  A Régina; M Demeule; A Laplante; J Jodoin; C Dagenais; F Berthelet; A Moghrabi; R Béliveau
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

6.  Use of rifampin for severe pruritus in children with chronic cholestasis.

Authors:  B Yerushalmi; R J Sokol; M R Narkewicz; D Smith; F M Karrer
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-10       Impact factor: 2.839

7.  Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system.

Authors:  Cataldo Doria; Lucio Mandalà; Jan D Smith; Giuseppe Caruana; Victor L Scott; Salvatore Gruttadauria; Mario Magnone; Ignazio R Marino
Journal:  Clin Transplant       Date:  2004-08       Impact factor: 2.863

8.  Long-lasting extracorporeal albumin dialysis in a child with end-stage renal disease and severe cholestasis.

Authors:  Etienne Javouhey; Bruno Ranchin; Alain Lachaux; Olivier Boillot; Xavier Martin; Daniel Floret; Pierre Cochat
Journal:  Pediatr Transplant       Date:  2008-04-22

9.  Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases.

Authors:  Romuald Bellmann; Clemens Feistritzer; Heinz Zoller; Ivo W Graziadei; Hubert Schwaighofer; Albert Propst; Christian J Wiedermann; Michael Joannidis
Journal:  ASAIO J       Date:  2004 Jul-Aug       Impact factor: 2.872

10.  Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study.

Authors:  Peter Faybik; Andreas Bacher; Sibylle A Kozek-Langenecker; Heinz Steltzer; Claus Georg Krenn; Sandra Unger; Hubert Hetz
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

View more
  6 in total

1.  Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents.

Authors:  Lindsey L Kennedy; Laura A Hargrove; Allyson B Graf; Taylor C Francis; Kyle M Hodges; Quy P Nguyen; Yoshi Ueno; John F Greene; Fanyin Meng; Victoria D Huynh; Heather L Francis
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

2.  Comparison of two different modes of molecular adsorbent recycling systems for liver dialysis.

Authors:  Euan Soo; Anja Sanders; Karlheinz Heckert; Tobias Vinke; Franz Schaefer; Claus Peter Schmitt
Journal:  Pediatr Nephrol       Date:  2016-07-09       Impact factor: 3.714

Review 3.  The role of molecular adsorbent recirculating system dialysis for extracorporeal liver support in children.

Authors:  Betti Schaefer; Claus Peter Schmitt
Journal:  Pediatr Nephrol       Date:  2012-11-22       Impact factor: 3.714

4.  Molecular Absorbent Recirculating System therapy (MARS®) in pediatric acute liver failure: a single center experience.

Authors:  Pierre Bourgoin; Aicha Merouani; Véronique Phan; Catherine Litalien; Michel Lallier; Fernando Alvarez; Philippe Jouvet
Journal:  Pediatr Nephrol       Date:  2013-12-06       Impact factor: 3.714

Review 5.  Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts.

Authors:  Faouzi Saliba; Rafael Bañares; Fin Stolze Larsen; Alexander Wilmer; Albert Parés; Steffen Mitzner; Jan Stange; Valentin Fuhrmann; Stefan Gilg; Tarek Hassanein; Didier Samuel; Josep Torner; Samir Jaber
Journal:  Intensive Care Med       Date:  2022-09-06       Impact factor: 41.787

Review 6.  Artificial liver support systems: what is new over the last decade?

Authors:  Juan José García Martínez; Karim Bendjelid
Journal:  Ann Intensive Care       Date:  2018-11-15       Impact factor: 6.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.